The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression: An Open-Label Trial
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Dopaminergic dysfunction is implicated in the pathophysiology of treatment-resistant depression. Although the efficacy of adjunctive pramipexole treatment has been demonstrated in treatment-resistant bipolar depression, such data are scarce for major depressive disorder (MDD). We recruited 17 patients with DSM-IV major depressive episode who have failed to respond to previous treatment with a selective serotonin reuptake inhibitor. Five patients were diagnosed as having bipolar II disorder and 12 as having unipolar MDD. Patients were monitored at an ambulatory care facility every two weeks until 12 weeks. Pramipexole was added to existing medication. Depression severity was assessed with the Hamilton Depression Rating Scale 21-item version (HDRS-21). The mean maximum dosage of pramipexole was 1.6 mg (SD 0.9). The HDRS-21 total score decreased from 19.4 (SD 3.8) at baseline to 7.2 (SD 5.4) at endpoint (P<0.000001). Twelve patients (71%) were responders based on the definition of 50% or more reduction in the HDRS-21 score. Ten patients (59%) remitted (HDRS-21 total score at endpoint<8). These results were almost unchanged when the sample was confined to patients with MDD. No serious adverse events were observed. Our findings indicate that pramipexole augmentation therapy may be effective and well tolerated in refractory depressed patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Open‐label studies and one controlled study showed that augmentation of antidepressants with dopamine agonist is efficacious, with the strongest evidence for pramipexole176–178.”
From Mechanisms and treatment of late-life depression (2019) · cites this paper as [177]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
Development of a Rating Scale for Primary Depressive Illness
HAMILTON, M. (1967) · British Journal of Social and Clinical Psychology · doi:10.1111/j.2044-8260.1967.tb00530.x · Cited by 8,410 · cited 14×
“The majority of responders demonstrated the 50% or more reduction of HDRS-21 total score within the first 4 weeks of pramipexole treatment.”
MethodInfluential(2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65186-5_300379 · Cited by 1,445
A functional anatomical study of unipolar depression
Drevets, W., Videen, T., Price, J., Preskorn, S., Carmichael, S., & Raichle, M. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-09-03628.1992 · Cited by 1,266 · cited 1×
“This finding provides support for a role of the central dopaminergic system in the pathophysiology of depression since cerebral metabolic activity in these regions has been found to be elevated in depression [21, 22].”
ResultThe role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“As dopamine is involved in the regulation of motivation, volition, interest/pleasure, and attention/concentration, all of which are likely to be impaired in depressed patients, reduced dopamine neurotransmission is implicated in the pathophysiology of depression and thought to play an important role in the treatment-r…”
Background(1997) · PubMed · Cited by 727
Treatment-Resistant Depression
(2015) · Encyclopedia of Psychopharmacology · doi:10.1007/978-3-642-36172-2_200431 · Cited by 488
Goldberg, J. F., Burdick, K. E., & Endick, C. J. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.3.564 · Cited by 372 · cited 2×
“Among the latter, pramipexole, a D2/D3 receptor agonist approved for the treatment of Parkinson’s disease and restless legs syndrome, has been demonstrated to have antidepressant efficacy as an adjunctive treatment in treatment-resistant bipolar depression in two randomized placebo-controlled trials [6, 7].”
BackgroundPramipexole for bipolar II depression: a placebo-controlled proof of concept study
Zarate, C. A., Payne, J. L., Singh, J., Quiroz, J. A., Luckenbaugh, D. A., Denicoff, K. D., Charney, D. S., & Manji, H. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.03.013 · Cited by 347 · cited 2×
“Among the latter, pramipexole, a D2/D3 receptor agonist approved for the treatment of Parkinson’s disease and restless legs syndrome, has been demonstrated to have antidepressant efficacy as an adjunctive treatment in treatment-resistant bipolar depression in two randomized placebo-controlled trials [6, 7].”
BackgroundSporn, J., Ghaemi, S. N., Sambur, M. R., Rankin, M. A., Recht, J., Sachs, G. S., Rosenbaum, J. F., & Fava, M. (2000) · Annals of Clinical Psychiatry · doi:10.1023/a:1009060800999 · Cited by 153 · cited 2×
“This study was also supported by Grant-in-Aid for Young Scientists (Start-up) from the JSPS (H. Hori).”
BackgroundInfluentialPramipexole in treatment‐resistant depression: a 16‐week naturalistic study
Lattanzi, L., Dell'Osso, L., Cassano, P., Pini, S., Rucci, P., Houck, P. R., Gemignani, A., Battistini, G., Bassi, A., Abelli, M., et al. (2002) · Bipolar Disorders · doi:10.1034/j.1399-5618.2002.01171.x · Cited by 150 · cited 1×
“Consistent with the present result, previous studies have shown that pramipexole augmentation in MDD brings a relatively rapid improvement in depressive symptoms [11, 13].”
ResultReversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole
Willner, P., Lappas, S., Cheeta, S., & Muscat, R. (1994) · Psychopharmacology · doi:10.1007/bf02245568 · Cited by 142 · cited 1×
“Supporting this, preclinical studies have demonstrated the effectiveness of dopamine agonists in depression [3, 4], and we also reported antidepressant-like and anxiolytic-like effects of cabergoline in rats [5].”
BackgroundRegional Cerebral Glucose Metabolic Abnormalities in Bipolar II Depression
Mah, L., Zarate, C. A., Singh, J. B., Duan, Y.-F., Luckenbaugh, D. A., Manji, H. K., & Drevets, W. C. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.06.009 · Cited by 132 · cited 1×
“This finding provides support for a role of the central dopaminergic system in the pathophysiology of depression since cerebral metabolic activity in these regions has been found to be elevated in depression [21, 22].”
ResultAntidepressant-like effects of dopamine agonists in an animal model of depression
Muscat, R., Papp, M., & Willner, P. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90119-k · Cited by 130 · cited 1×
“Supporting this, preclinical studies have demonstrated the effectiveness of dopamine agonists in depression [3, 4], and we also reported antidepressant-like and anxiolytic-like effects of cabergoline in rats [5].”
BackgroundPramipexole in Psychiatry: A Systematic Review of the Literature
Aiken, C. B. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n0810 · Cited by 129 · cited 3×
“Indeed, there is some evidence suggesting a dose-response relationship of pramipexole [19].”
BackgroundResultInfluentialBromocriptine treatment of tricyclic and heterocyclic antidepressant-resistant depression
Inoue, T., Tsuchiya, K., Miura, J., Sakakibara, S., Denda, K., Kasahara, T., & Koyama, T. (1996) · Biological Psychiatry · doi:10.1016/0006-3223(95)00666-4 · Cited by 73 · cited 1×
“The Scientific World Journal Volume 2012, Article ID 372474, 8 pages doi:10.1100/2012/372474 The cientificWorldJOURNAL Clinical Study The Efficacy of Pramipexole, a Dopamine Receptor Agonist, as an Adjunctive Treatment in Treatment-Resistant Depression:”
BackgroundInfluentialRopinirole in treatment-resistant depression: a 16-week pilot study
Cassano, P., Lattanzi, L., Fava, M., Navari, S., Battistini, G., Abelli, M., & Cassano, G. B. (2005) · The Canadian Journal of Psychiatry · doi:10.1177/070674370505000612 · Cited by 73 · cited 2×
“This study was also supported by Grant-in-Aid for Young Scientists (Start-up) from the JSPS (H. Hori).”
BackgroundInfluentialOpen pergolide treatment of tricyclic and heterocyclic antidepressant-resistant depression
Izumi, T., Inoue, T., Kitagawa, N., Nishi, N., Shimanaka, S., Takahashi, Y., Kusumi, I., Odagaki, Y., Denda, K., Ohmori, T., et al. (2000) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00199-8 · Cited by 65
Chiba, S., Numakawa, T., Ninomiya, M., Yoon, H. S., & Kunugi, H. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1894-8 · Cited by 42 · cited 1×
“Supporting this, preclinical studies have demonstrated the effectiveness of dopamine agonists in depression [3, 4], and we also reported antidepressant-like and anxiolytic-like effects of cabergoline in rats [5].”
BackgroundSelf-citationPramipexole for stage 2 treatment-resistant major depression: An open study
Inoue, T., Kitaichi, Y., Masui, T., Nakagawa, S., Boku, S., Tanaka, T., Suzuki, K., Nakato, Y., Usui, R., & Koyama, T. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.035 · Cited by 34 · cited 5×
“Furthermore, efficacy of a dopamine agonist in refractory MDD patients whose degree of treatment resistance is explicitly defined as stage II or more has been examined only in one open trial [13], although the other studies investigating adjunctive pramipexole therapy in treatment-resistant depression may have include…”
BackgroundResultInfluentialMah, L., Zarate, C. A., Nugent, A. C., Singh, J. B., Manji, H. K., & Drevets, W. C. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001203 · Cited by 34 · cited 1×
“A recent neuroimaging study, however, showed that clinical improvement with pramipexole augmentation in bipolar depression was associated with a reduction in regional metabolism in orbitofrontal cortex, ventrolateral prefrontal cortex, and anteromedial prefrontal cortex [20].”
Comparison of pramipexole, fluoxetine, and placebo in patients with major depression
(2000) · doi:10.1002/(sici)1520-6394(2000)11:2<58::aid-da2>3.0.co;2-h
Research works printed but not linked: 1
- 1997, Journal of Clinical Psychiatry, 58, 23
Cited by
Mechanisms and treatment of late-life depression
Alexopoulos, G. S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0514-6 · Cited by 592
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
Nousen, E. K., Franco, J. G., & Sullivan, E. L. (2013) · Neuroendocrinology · doi:10.1159/000355632 · Cited by 123
Biochemical markers subtyping major depressive disorder
Kunugi, H., Hori, H., & Ogawa, S. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12299 · Cited by 114
“Our group provided preclinical and clinical evidence suggesting that dopamine agonists are effective for treatment-resistant depression.(28,29) Collectively, dopamine plays an essential role in the pathophysiology of MDD and there might be a subgroup of ‘dopamine agonist-responsive depression’.”
BackgroundSelf-citationRole of Mesolimbic Brain-Derived Neurotrophic Factor in Depression
Koo, J. W., Chaudhury, D., Han, M.-H., & Nestler, E. J. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.05.020 · Cited by 112
Metadata
- Authors
- Hori, H., & Kunugi, H.
- Affiliations
- National Center of Neurology and Psychiatry (JP)
- Corresponding author
- Kunugi, Hiroshi
- Venue
- The Scientific World Journal
- Publisher
- Wiley
- Published
- 2012
- Volume
- 2012
- Pages
- 1-8
- ISSN
- 1537-744X (ISSN-L)
- PMC
- PMC3415165
- OpenAlex
- W2108580074
- Cited by
- 62
- References
- 22
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 6 · 2023: 3 · 2022: 2 · 2021: 19 · 2020: 1 · 2019: 6 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 4 · 2014: 6 · 2013: 6
- FWCI
- 3.76
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- The Scientific World JOURNAL (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Funders
- Health and Labor Sciences Research Grants
- Mitsubishi Pharma Research Foundation
- CREST
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- pramipexole, dopamine agonists, treatment-resistant depression, major depressive disorder, bipolar II disorder, adjunctive therapy, augmentation therapy, dopaminergic dysfunction, remission, adverse events
- MeSH terms
- Pramipexole, Adult, Depression, Female, Humans, Male, Middle Aged, Dopamine Agonists, Benzothiazoles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
